Hangzhou Xingsai Ruizhen Biotechnology
Cell therapy and regenerative medicine translation platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | CNY100m | Early VC | |
| Total Funding | 000k | ||
Hangzhou Xingsai Ruizhen Biotechnology (Celregen) is a platform company focused on cell therapy and regenerative medicine. Founded in July 2022, the company was incubated by the New Drug Innovation Fund of Fosun Health Capital. Its headquarters are in Hangzhou, with a research and development center located in Shanghai. The Chairman is Cui Zhiping, who also serves as a Fosun Global Partner and CEO of the Fosun New Drug Fund.
Celregen operates on a business model that combines in-house research and development with the in-licensing of external technologies ("引进+自研"). The company's primary focus is on developing and commercializing regenerative medicine products for ophthalmology and metabolic diseases, aiming to solve issues related to organ transplant shortages and immune rejection. A key area of its pipeline is tissue regeneration, with product candidates for the cornea, pancreatic islets, and liver. Additionally, Celregen is active in tumor therapy, collaborating with scientists to develop stem cell-derived CAR-NK therapies.
A significant milestone for the company was the September 2022 exclusive license agreement with Japanese startup Cellusion Inc. This agreement grants Celregen the exclusive rights to develop, manufacture, and commercialize CLS001, a novel treatment for bullous keratopathy, in the Greater China region (Mainland China, Hong Kong, Macau, and Taiwan). CLS001 is a regenerative therapy that uses induced pluripotent stem cells (iPSCs) to create corneal endothelial cell substitutes. The deal is valued at potentially over $100 million, including upfront payments, development and sales milestones, and tiered royalties. The company secured CNY 45 million in a seed funding round in August 2022 from Fosun Health Capital and Shanghai Creation Investment Management. This was followed by a nearly CNY 100 million Angel round in March 2025.
Keywords: regenerative medicine, cell therapy, iPSC, corneal endothelial cell therapy, bullous keratopathy, tissue regeneration, tumor therapy, CAR-NK, Fosun Pharma, stem cells, CLS001, drug development, biotechnology, life sciences, Hangzhou, Shanghai, Greater China, in-licensing, clinical translation, metabolic diseases, ophthalmology, organ transplant alternatives